Market Size, R&D Spend & the Outsourcing Shift

Drug development is not a single market; it is the engine that feeds the wider medicines market. The number that matters most for a developer's business plan is research and development spend, because that is the pool your programme competes inside for capital, lab capacity, and clinical sites. Global pharmaceutical R&D spend reached roughly $251 billion in 2022 and is projected to climb toward $350 billion by 2029 (Statista, 2024). That spend is increasingly handled by specialists rather than in-house teams, which is exactly why a first-time founder can credibly run a programme without owning a single laboratory.

The clearest signal of that shift is the contract research organisation (CRO) market. It was valued at about $45.33 billion in 2025 and is forecast to reach $83.31 billion by 2033 at an 8.04% compound annual growth rate (Grand View Research, 2025). Large pharma now outsources close to half of its R&D activity, and small companies often outsource almost all of it. For your plan, that means the build-versus-buy decision is mostly settled in favour of buy at the early stage, and your operating model is really a procurement and programme-management model.

The headline cost figure is widely quoted and widely misread. Deloitte's running benchmark put the average capitalized cost of bringing a new drug to market at about $2.3 billion in 2022, a 15% jump year on year (Deloitte via GEN, 2023). A 2025 analysis in JAMA Network Open (2025) looked at 2019 approvals and found a mean of $1.31 billion but a median of only $708 million once cost of capital and discontinued projects were included. The gap between mean and median tells you something a generic guide will not: a handful of very expensive programmes skew the average, and a focused single-asset developer can target the lower half of that distribution. No founder raises $2 billion in one go. You raise the cost of the next gate.

Where founders win in this market is rarely on raw spend. It is on selecting a target with strong biological rationale, picking an indication where the regulatory path and clinical endpoints are well understood, and being honest about attrition. Programmes that respect those three constraints raise more efficiently and partner sooner, which is the entire point of a credible plan.

Choosing an Indication & Modality

The two decisions that shape a drug-development plan more than any other are which disease you target and what kind of molecule you develop. They set your cost, your timeline, your regulatory route, and the kind of investor who will back you. A generic pharmaceutical guide treats these as interchangeable; in practice they pull the entire financial model in different directions, and a plan that does not commit to a specific indication and modality reads as unfinished.

The indication decision

A well-chosen indication has clear, accepted clinical endpoints, a defined patient population you can recruit, and a regulatory precedent that tells you what an approvable data package looks like. Oncology and rare diseases attract a large share of capital because the unmet need is high and accelerated pathways may apply, but their trials are among the most expensive per patient, which is exactly why the Phase 1 budget line spans such a wide range. A common-disease indication may be cheaper per patient but demands far larger and longer trials to show a meaningful effect, raising total cost even as per-patient cost falls. The plan should name the indication, justify it on biological and commercial grounds, and state the primary endpoint the lead asset will be measured against.

Rare and orphan indications carry specific incentives worth costing into the model. Orphan designation in the US and the EU can bring fee waivers, tax credits on qualifying clinical costs, and extended market exclusivity, all of which change the risk-adjusted return and the size of round you can justify. Where your indication qualifies, that designation belongs in the regulatory and financial sections, not as a footnote.

The modality decision

Modality is the second axis. A small molecule is generally cheaper to manufacture and to move into the clinic, with well-trodden chemistry and toxicology. Biologics, including antibodies, sit higher on cost and complexity because manufacturing living-cell-derived material is harder to scale and to characterise. Advanced therapy medicinal products such as cell and gene therapies sit higher still, with bespoke manufacturing and longer regulatory engagement, and they routinely fall into mandatory centralised review in the EU. Your modality therefore decides whether the manufacturing line in your budget is a five-figure or a seven-figure number at the same stage of development, and a serious investor will expect that to be reflected honestly.

Build vs Outsource: CRO & CDMO Partners

Because outsourced R&D now grows faster than in-house R&D, the operating model in a modern drug-development plan is largely a partner-management model. The question is not whether to outsource but what to outsource, to whom, and how to keep control of quality, timeline, and intellectual property while doing so. Big pharma outsources close to half its R&D activity and smaller companies often approach 100%, so a virtual model is the norm rather than a compromise.

The partners fall into two broad groups. Contract research organisations (CROs) run your studies, from discovery and preclinical work through clinical operations. Contract development and manufacturing organisations (CDMOs) make your drug substance and product to the required quality standard. The named market leaders a plan should be aware of include:

• IQVIA, the largest CRO by revenue, with end-to-end clinical and data capabilities and global trial reach.
• ICON plc, a top-tier full-service CRO strong across clinical development phases.
• Labcorp Drug Development, broad services spanning diagnostics and the full development lifecycle.
• Charles River Laboratories, a leader in early discovery, preclinical, and safety assessment, often the first partner a preclinical developer engages.
• Parexel, a major clinical CRO with deep regulatory consulting expertise.

Boutique CROs compete with these on niche expertise and responsiveness, which can matter more than scale for a single early asset. The trade-off your plan should articulate is straightforward: large integrated providers offer breadth, vertical integration, and procurement power, while specialists offer focus and attention. Many founders run a hybrid, using a discovery-focused partner such as Charles River for IND-enabling work and a clinical CRO for the trial itself.

Whatever the mix, three controls belong in the operations section. First, intellectual property and data ownership must sit with your company, written into every contract. Second, quality oversight stays in-house even when execution is outsourced, because the regulator holds the sponsor responsible. Third, the manufacturing and quality timeline is treated as a gating dependency on the clinical timeline, since securing GMP material and Qualified Person release frequently takes longer than founders expect and can delay first dosing. Costing these partners line by line, rather than as a single estimate, is one of the clearest signals to an investor that the plan was built by someone who has run a programme.

Questions Founders Ask First

These are the questions that come up in nearly every early conversation with a drug-development founder. Short, specific answers here; the funding and regulatory detail follows below.

How long until there is any revenue?

For a pure developer, often years, and frequently never from product sales directly. Value is realised at a deal: an out-licence, a co-development agreement, or an acquisition. The plan's job is to show the inflection that triggers that deal, not to pretend a launch is imminent. With discovery-to-approval running 10 to 15 years and only about 1 in 10 clinical-stage candidates reaching market, the commercial story is a value-creation story, not a near-term sales forecast.

What is the single biggest line item?

Clinical trials, by a wide margin once you reach the clinic. A Phase 3 study alone can absorb up to 60% of total development cost, and Phase 1 to Phase 3 together dominate the budget. That is why early plans concentrate on getting one asset cleanly to a Phase 1 or early Phase 2 readout, where the data is most valuable to a partner relative to the capital consumed.

Do I need a PhD or an MD to do this?

Not personally, but your team needs deep scientific and regulatory credibility, and investors weight that heavily. The most common successful archetype is a scientist-founder paired early with an experienced drug developer or chief medical officer. Bringing that experience on board late is a frequent and expensive mistake, so the management section of your plan carries unusual weight in this sector.

Is biotech funding actually available right now?

Yes, but unevenly. Global biotech venture investment rose to roughly $21.4 billion in 2024 from $16.1 billion in 2023, with mega-rounds above $100 million making up about 66% of the total (BioSpace, 2025). The market is two-speed: ample capital for a small number of perceived winners and a long tail that struggles to raise at all. A sharp, de-risked plan is how you move toward the first group.

What It Costs, Stage by Stage

The honest answer to "how much does it cost to start a drug-development company" is two numbers. The full programme cost, spread over a decade or more and funded across many rounds, runs into the hundreds of millions to low billions. The cost you actually budget and raise for at the outset, taking a validated idea to a first-in-human-ready package, is far smaller. For a lean, virtual developer that figure typically sits between $250,000 and $6 million (about £200,000 to £4.5 million), depending on modality, indication, and how much chemistry and toxicology you outsource.

Biologics and advanced therapies sit at the upper end because manufacturing of clinical material is more complex and more expensive than for a small molecule. A small-molecule programme targeting a well-characterised pathway can reach an Investigational New Drug (IND) filing for materially less than a cell or gene therapy aiming at the same gate.

Cost Breakdown to First-in-Human

• Target validation, medicinal chemistry & hit-to-lead: $150K-$800K (£120K-£640K)
• IND-enabling preclinical (GLP toxicology, ADME, pharmacology): $300K-$1.5M (£240K-£1.2M)
• GMP material / API for first-in-human dosing: $200K-$1M (£160K-£800K)
• Phase 1 first-in-human clinical trial: $1.5M-$6M (£1.2M-£4.8M)
• Regulatory & QA (IND/CTA preparation, consultants): $80K-$400K (£64K-£320K)
• Intellectual property (patent filing & global prosecution): $50K-$250K (£40K-£200K)
• Core team salaries (12-18 months of runway): $400K-$1.8M (£320K-£1.4M)

Two of those lines deserve emphasis. First, the Phase 1 range is wide because trial cost scales with the number of patients, the complexity of the protocol, and the therapeutic area; analyses tying cost to trial characteristics show oncology and rare-disease studies running well above simpler indications (JAMA Network Open, 2025). Second, intellectual property is cheap relative to the asset it protects but expensive to neglect; a thin patent position undermines every later financing and partnership conversation, so it belongs in the founding budget, not as an afterthought.

When we build the financial model inside a bespoke plan, we treat each of these as a tranche tied to a gate rather than a lump sum. That structure is what dilutive investors expect to see, and it is also what keeps a young company from over-raising and giving away too much equity before the data justifies the valuation.

Funding Routes & Grant Programmes

Drug development is funded differently from most businesses on this site. The asset itself is rarely financed by a bank loan, because there is no near-term cash flow to service debt and no hard collateral beyond intellectual property. Instead the capital stack blends equity, non-dilutive grants, and selective debt, layered by stage.

Venture capital and the round structure

Dilutive venture capital is the workhorse. The median biotech venture round sat near $93 million in the first quarter of 2025, with Series A medians in the $50 to $80 million band as the market recovered (BioPharma Dive, 2025). Those headline figures are skewed by large platform rounds; a single-asset seed to reach an IND-enabling inflection is often a low-single-digit-million raise. The discipline that wins is matching the size of each round to the cost of the next gate plus a sensible buffer, so you never raise a Phase 2 round to fund a candidate-selection decision.

Non-dilutive grants and awards

• United States: SBIR and STTR awards channel federal research funding to small companies; NIH and BARDA grants support specific disease areas and biodefence. These are competitive but non-dilutive.
• United Kingdom: Innovate UK and the Biomedical Catalyst fund translational projects; the British Business Bank's Start Up Loans scheme (up to £25,000 at 6% fixed) can seed company formation and early overheads, though not a full trial.
• Disease foundations: patient and disease charities co-fund programmes in their indication, often with favourable terms and useful clinical networks.

Where loans and the SBA do fit

US Small Business Administration 7(a) loans (up to $5 million) and 504 loans are poorly matched to the drug asset itself, but they can finance the ancillary, cash-generating parts of a wider venture: a services arm, laboratory build-out for a CRO-style offering, or equipment. Venture debt from specialist lenders is more relevant to the R&D company and is usually layered on top of an equity round to extend runway between gates rather than to replace equity. In the UK, the Enterprise Investment Scheme (EIS) and Seed Enterprise Investment Scheme (SEIS) give individual investors generous tax relief, which materially widens the pool of early backers; our Research and Content service regularly prepares the supporting plan and financials for SEIS and EIS rounds.

How Developers Make Money

A drug-development company usually does not sell a product for years, and frequently never sells one directly. Its revenue model is built around the value of the asset rather than units shipped. Understanding which of the following routes your plan assumes changes the entire financial model, so this is one of the first decisions to fix.

• Out-licensing: grant a partner the right to develop and commercialise your asset in exchange for an upfront payment, development, regulatory and sales milestones, and a royalty on net sales, commonly in the 5% to 15% range.
• Co-development: share later-stage cost and downstream economics with a larger partner who brings capital and commercial reach.
• Acquisition: the company itself is bought, typically after a value-creating clinical readout; this is the most common full exit for a focused developer.
• Self-commercialisation: taking the drug to market yourself, which adds an enormous capital requirement and a full commercial organisation, and is rare for a first-time founder.

Margins only become relevant once a drug is marketed. Branded medicines carry gross margins of roughly 70% to 90% because the marginal cost of manufacture is low against the price of a protected, on-patent product, while the corporate net margin of large profitable pharma companies tends to land around 20% to 30% after the cost of the broader pipeline. A developer's plan should be explicit that it is pre-profit until a deal or approval, and should value the company on the risk-adjusted economics of the lead asset rather than on early cash flow.

A worked deal example

Take a composite preclinical developer with a Phase-1-ready oncology candidate. It out-licenses the asset to a mid-cap partner for a $12 million upfront payment, up to $180 million in development, regulatory and commercial milestones, and a 9% royalty on eventual net sales. Against roughly $7.5 million raised across a seed and Series A, the upfront alone returns the invested capital before a single dose is sold at commercial scale, with the milestones and royalty representing the real upside. The financial model in your plan should show exactly this kind of milestone-weighted value, discounted for the probability of success at each gate, because that is how a sophisticated investor underwrites the opportunity.

Regulatory Pathway: FDA, MHRA & EMA

Regulation is the spine of a drug-development plan. Unlike most businesses, where a licence is a box to tick, here the regulatory pathway defines your timeline, your budget, and the milestones your investors are funding. The plan should name the specific filings, the agency, and the review clock at each gate.

United States (FDA)

• Investigational New Drug (IND) application to the FDA before first-in-human dosing. There is no FDA filing fee for the IND, but the enabling package commonly costs $300K-$1.5M. The FDA has a 30-day safety review window before trials may begin.
• Phase 1, 2 and 3 clinical trials under that IND, escalating in size and cost, with the FDA able to place a clinical hold at any point.
• New Drug Application (NDA) for small molecules or Biologics License Application (BLA) for biologics to seek approval. The FY2026 PDUFA user fee is $4,682,003 for an application requiring clinical data and $2,341,002 for one that does not (Federal Register, FY2026).
• Standard review takes roughly 10 months; priority review roughly 6 months. A pre-approval inspection of your manufacturing under current Good Manufacturing Practice (cGMP) precedes launch.

United Kingdom (MHRA)

• Clinical Trial Authorisation (CTA) via the MHRA's Combined Review service, a single submission assessed jointly by the MHRA and a Research Ethics Committee. Since January 2022 all new clinical trial applications must use this route.
• The statutory clock is up to 60 days; recent MHRA performance metrics show an average of about 28 days for initial applications, with 100% inside statutory timelines (GOV.UK / MHRA).
• Marketing Authorisation (MA) from the MHRA to sell in the UK, with an International Recognition Procedure available to lean on approvals from trusted regulators.
• Manufacturer's or Importer's Authorisation (MIA) and Qualified Person (QP) certification before any UK supply.

European Union (EMA)

• Clinical Trial Application under the Clinical Trials Regulation (EU No 536/2014), submitted once through the Clinical Trials Information System (CTIS) and assessed jointly across the member states where you intend to run sites.
• Centralised Marketing Authorisation through the EMA is mandatory for new active substances in oncology, advanced therapy medicinal products, orphan drugs and other in-scope categories, giving one approval valid across the EU.
• Since Brexit, UK and EU procedures run independently, so a programme targeting both markets budgets for two regulatory tracks rather than one.

A practical point that competitors' templates skip: the regulatory and manufacturing (CMC) timelines often gate the clinical timeline, not the other way round. Securing GMP material and a Qualified Person can take longer than expected, and a plan that assumes instant supply will slip. We build these dependencies into the operational timeline so the funding ask matches reality.

Where Drug Programmes Go Wrong

Roughly nine in ten candidates that enter clinical trials fail, and the reasons are well documented rather than mysterious. A strong plan shows the investor you understand these failure modes and have designed around them.

• Treating efficacy as solved. Lack of clinical efficacy accounts for an estimated 40% to 50% of failures, with unmanageable toxicity adding about 30% (PMC, 2022). Plans that gloss over the efficacy hypothesis and the killer experiment that tests it lose credibility fast.
• Cutting preclinical corners to save cash. Rushing IND-enabling toxicology to preserve runway tends to produce costlier failures later in human trials. The cheap saving early becomes an expensive surprise in Phase 2.
• Budgeting the whole programme, not the next gate. Building the ask around the full $2 billion figure rather than the cost of the next inflection signals inexperience and almost guarantees a mispriced round.
• No clear milestones. Deploying capital without a value-creating endpoint per raise is one of the most common causes of failure; each tranche should buy a specific, datable inflection.
• Underestimating manufacturing and quality. GMP supply, CMC development and QP release routinely take longer and cost more than first-time founders assume, and they sit on the critical path to the clinic.
• Overpromising platform breadth. Claiming a platform that will yield many drugs, instead of de-risking one lead asset to a credible inflection, invites the skepticism that has followed firms that failed to deliver on bold technology claims.

The throughline is focus. The developers who raise efficiently pick one lead asset, define the next inflection, fund precisely to it, and tell that story without inflation. Our writing process is built to enforce exactly that discipline on the page.

Sample Plan Preview

Here is an extract from a drug-development business plan written by our team, so you can see the level of specificity a serious investor expects:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for a drug-development venture:

• Executive Summary, The lead asset, the target product profile, and the inflection this raise funds, written to land in 60 seconds.
• Company & Programme Overview, Legal structure, the virtual operating model, and the asset's mechanism and rationale.
• Scientific & Market Analysis, Target validation, indication, competitive set, and the R&D-spend context above.
• Development Plan & Stage-Gates, Preclinical through clinical milestones, each with cost, timeline, and a go/no-go decision.
• Regulatory Strategy, IND/CTA, NDA/BLA or MA, and the agency, fee, and review clock at each gate.
• CMC & Operations, Manufacturing, CRO partners, quality, and the dependencies that gate the clinical timeline.
• Intellectual Property, Patent family, freedom-to-operate posture, and prosecution timeline.
• Management Team, Scientific founders, the experienced developer or CMO, advisory board, and key hires planned.

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with a milestone-weighted, risk-adjusted valuation, a tranche-by-tranche use of funds, cash flow, and the runway map between gates that drug-development investors expect. You can also pair this plan with a deck from our business plan writer service, or browse adjacent guides such as the biotech drug discovery business plan template if your focus is earlier-stage discovery, or the biopharmaceutical business plan template for a biologics-led programme.

Frequently Asked Questions